Glaxosmithkline Pharmaceuticals Ltd (GLAXO) — shareholding pattern, promoter holding, financials and share price
About Glaxosmithkline Pharmaceuticals Ltd (GLAXO)
Glaxosmithkline Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as GLAXO and on the BSE under scrip code 500660. Its ISIN is INE159A01016.
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)
GlaxoSmithKline Pharmaceuticals Limited (GSK India) is a leading Indian subsidiary of GSK plc that researches, manufactures, markets and distributes prescription pharmaceuticals, vaccines and specialty medicines across General Medicines, Vaccines and Specialty segments, operating manufacturing facilities at Nashik and Thane, supported by 20 CMOs and regional commercial hubs serving HCPs, hospitals and retail channels nationwide.
Q3 FY26 financials show revenue of ₹1,023 crore (+8.1% YoY), EBITDA of ₹368 crore with a 35.9% margin (up 520 bps YoY) and PAT before exceptional of ₹277 crore (+21.3%), driven by gross margin improvement, operating leverage and field productivity gains; the company reported a strong cash balance of ₹2,426 crore and EPS of ₹16.36 for the quarter.
Listed peers in Pharmaceuticals: Ipca Laboratories Ltd, Ajanta Pharma Ltd, Gland Pharma Ltd, J B Chemicals & Pharmaceuticals Ltd, Emcure Pharmaceuticals Ltd, Wockhardt Ltd.
Valuation & Returns
10 Jul 2026At ₹2,435.5 a share on 10 Jul 2026, Glaxosmithkline Pharmaceuticals Ltd (GLAXO) was valued at a price-to-earnings ratio of 39.83x against an industry P/E of 36.41x and a price-to-book of 18.2x on a book value of ₹133.85 per share as of Mar 2026. Solomo computes return on equity of 45.69% and return on capital employed of 61.23% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 39.83x
- Industry P/E
- 36.41x
- P/B
- 18.2x
- EPS (TTM)
- ₹61.15
- Book value / share
- ₹133.85
- ROE
- 45.69%
- ROCE
- 61.23%
- ROA
- 23.96%
- Debt / equity
- 0.01x
- Dividend yield
- 2.34%
- EBITDA margin
- 38.6%
- 52-week range
- ₹2,088 – ₹3,266.95
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Glaxosmithkline Pharmaceuticals Ltd (GLAXO) reported revenue of ₹3,822 crore, net profit of ₹1,036 crore and earnings per share of ₹61.15. That compares with revenue of ₹3,749 crore and net profit of ₹928 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹995 crore and net profit ₹278 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 3,278 | 3,252 | 3,454 | 3,749 | 3,822 |
| Net profit (₹ cr) | 1,695 | 611 | 590 | 928 | 1,036 |
| EPS (₹) | 100.04 | 36.05 | 34.83 | 54.75 | 61.15 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 2.65% | 5.35% | 5.62% | 1.93% |
| Profit growth | 13.00% | 28.69% | 18.72% | 11.69% |
| Stock price CAGR | 4% | 10% | 21% | -21% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 75% of Glaxosmithkline Pharmaceuticals Ltd (GLAXO) (unchanged from the previous quarter), foreign institutional investors (FII) hold 4.79% and domestic institutional investors (DII) hold 7.8%. Market capitalisation was ₹41,259 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: LICI ASM NON PAR 1.08%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 75% | - | 4.79% | 7.8% | 25% |
| Mar 2026 | 75% | - | 4.62% | 7.68% | 25% |
| Dec 2025 | 75% | - | 4.64% | 7.7% | 25% |
| Sep 2025 | 75% | - | 4.8% | 7.75% | 25% |
| Jun 2025 | 75% | - | 4.89% | 7.7% | 25% |
| Mar 2025 | 75% | - | 4.52% | 7.79% | 25% |
| Dec 2024 | 75% | - | 4.5% | 7.3% | 25% |
| Sep 2024 | 75% | - | 4.36% | 7.34% | 25% |